JP2024543379A5 - - Google Patents
Info
- Publication number
- JP2024543379A5 JP2024543379A5 JP2024527357A JP2024527357A JP2024543379A5 JP 2024543379 A5 JP2024543379 A5 JP 2024543379A5 JP 2024527357 A JP2024527357 A JP 2024527357A JP 2024527357 A JP2024527357 A JP 2024527357A JP 2024543379 A5 JP2024543379 A5 JP 2024543379A5
- Authority
- JP
- Japan
- Prior art keywords
- psilocybin
- dose
- weeks
- administration
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277407P | 2021-11-09 | 2021-11-09 | |
| US63/277,407 | 2021-11-09 | ||
| US202163284973P | 2021-12-01 | 2021-12-01 | |
| US63/284,973 | 2021-12-01 | ||
| PCT/US2022/048713 WO2023086252A1 (en) | 2021-11-09 | 2022-11-02 | Treatment of treatment resistant depression with psilocybin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543379A JP2024543379A (ja) | 2024-11-21 |
| JP2024543379A5 true JP2024543379A5 (https=) | 2025-10-24 |
Family
ID=84799979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527357A Pending JP2024543379A (ja) | 2021-11-09 | 2022-11-02 | サイロシビンによる治療抵抗性うつ病の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250000881A1 (https=) |
| EP (1) | EP4429671A1 (https=) |
| JP (1) | JP2024543379A (https=) |
| KR (1) | KR20240110816A (https=) |
| AU (1) | AU2022387053A1 (https=) |
| CA (1) | CA3237885A1 (https=) |
| MX (1) | MX2024005632A (https=) |
| WO (1) | WO2023086252A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| TW202304466A (zh) * | 2021-03-30 | 2023-02-01 | 英商康派斯開拓者公司 | 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) * | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| GB2588505B (en) * | 2017-10-09 | 2022-08-03 | Compass Pathfinder Ltd | Preparation of psilocybin |
| US12377112B2 (en) * | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| TW202304466A (zh) * | 2021-03-30 | 2023-02-01 | 英商康派斯開拓者公司 | 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法 |
-
2022
- 2022-11-02 WO PCT/US2022/048713 patent/WO2023086252A1/en not_active Ceased
- 2022-11-02 MX MX2024005632A patent/MX2024005632A/es unknown
- 2022-11-02 US US18/703,950 patent/US20250000881A1/en active Pending
- 2022-11-02 JP JP2024527357A patent/JP2024543379A/ja active Pending
- 2022-11-02 CA CA3237885A patent/CA3237885A1/en active Pending
- 2022-11-02 EP EP22835920.4A patent/EP4429671A1/en active Pending
- 2022-11-02 AU AU2022387053A patent/AU2022387053A1/en active Pending
- 2022-11-02 KR KR1020247017950A patent/KR20240110816A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024543379A5 (https=) | ||
| JP2023123773A5 (https=) | ||
| JP2008535867A5 (https=) | ||
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| KR20210117345A (ko) | Jak 저해제를 포함하는 제약 조성물 | |
| US5512572A (en) | Anti-ischemic medicament | |
| JP2014516942A5 (https=) | ||
| JP2023522010A5 (https=) | ||
| JP2024515829A5 (https=) | ||
| JP2025508071A5 (https=) | ||
| JP2024544538A5 (https=) | ||
| JP2023011769A5 (https=) | ||
| JP2023509698A5 (https=) | ||
| CA2306985A1 (en) | Novel use of compounds for anti-pruritic activity | |
| Pöllmann et al. | Chronic paroxysmal hemicrania: the first possible bilateral case | |
| JP2025509278A5 (https=) | ||
| WO2019032626A1 (en) | Methods of treatment | |
| JP2025504219A5 (https=) | ||
| JPS625913A (ja) | ジヒドロピリジン含有製剤 | |
| TW202237103A (zh) | 用於治療抑鬱症的ｎｒ２ｂ－ｎｍｄａ受體ｎａｍ之劑量方案 | |
| JP2025134747A5 (https=) | ||
| ES2309357T3 (es) | Nueva combinacion sinergica que comprende roflumilast y formoterol. | |
| Brunner et al. | Effectiveness of sustained-action isosorbide dinitrate on exercise-induced myocardial ischemia | |
| JP2023527358A5 (https=) | ||
| JP2022518288A5 (https=) |